164 related articles for article (PubMed ID: 12969794)
1. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice.
McLaughlin PJ; Levin RJ; Zagon IS
Cancer Lett; 2003 Sep; 199(2):209-17. PubMed ID: 12969794
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stucki JK; Zagon IS
Head Neck; 2012 Apr; 34(4):513-9. PubMed ID: 21584896
[TBL] [Abstract][Full Text] [Related]
3. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
McLaughlin PJ; Zagon IS
Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459
[TBL] [Abstract][Full Text] [Related]
4. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
Zagon IS; McLaughlin PJ
Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
[TBL] [Abstract][Full Text] [Related]
5. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration.
McLaughlin PJ; Stack BC; Braine KM; Ruda JD; Zagon IS
Int J Oncol; 2004 Jan; 24(1):227-32. PubMed ID: 14654962
[TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
7. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.
McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS
Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790
[TBL] [Abstract][Full Text] [Related]
9. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
[TBL] [Abstract][Full Text] [Related]
10. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stack BC; Levin RJ; Fedok F; Zagon IS
Cancer; 2003 Apr; 97(7):1701-10. PubMed ID: 12655527
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
[TBL] [Abstract][Full Text] [Related]
12. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
13. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor.
McLaughlin PJ; Levin RJ; Zagon IS
Int J Oncol; 1999 May; 14(5):991-8. PubMed ID: 10200353
[TBL] [Abstract][Full Text] [Related]
14. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
15. The opioid growth factor receptor in human head and neck squamous cell carcinoma.
McLaughlin PJ; Levin RJ; Zagon IS
Int J Mol Med; 2000 Feb; 5(2):191-6. PubMed ID: 10639600
[TBL] [Abstract][Full Text] [Related]
16. Opioid growth factor regulates the cell cycle of human neoplasias.
Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
[TBL] [Abstract][Full Text] [Related]
17. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor.
McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS
Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840
[TBL] [Abstract][Full Text] [Related]
18. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
19. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice.
Zagon IS; Hytrek SD; Smith JP; McLaughlin PJ
Cancer Lett; 1997 Jan; 112(2):167-75. PubMed ID: 9066724
[TBL] [Abstract][Full Text] [Related]
20. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
Zagon IS; Ruth TB; McLaughlin PJ
Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
